MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation ROA Ratio 2011-2026 | ADMP
Annual ROA Ratio Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -242.23 | -119.66 | -160.01 | -61.26 | -66.84 | -49.68 | -51.44 | -112.52 | -53.94 | -2050.21 | -2907.79 | -402.62 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -49.68 | -2907.79 | -523.18 |
Quarterly ROA Ratio Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -186.51 | -218.48 | -117.59 | -145.02 | -136.2 | -103.36 | -61.11 | -97.92 | -107.3 | -134.55 | -102.15 | -116.79 | -94.61 | -68.91 | -49.38 | -64.59 | -65.16 | -65.62 | -44.89 | -58.06 | -56.02 | -49.06 | -34.07 | -51.65 | -56.07 | -61.52 | -49.67 | -75.77 | -84.28 | -99.38 | -82.37 | -98.84 | -89.21 | -81.33 | -50.85 | -88.3 | -72.73 | -50.39 | -252.73 | -429.66 | -1156.21 | -1141.19 | -1539.68 | -1723.8 | -1995.76 | -1793.23 | -398.49 | -999.42 | -395.32 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -34.07 | -1995.76 | -308.07 |
ROA Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-141.05 | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-48.08 | - | 7.5 % | $ 6.35 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.34 | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
-11.38 | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
-10.69 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-61.13 | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-13.11 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-50.69 | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
8.78 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-47.69 | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-29.73 | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-110.24 | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-2.52 | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Cronos Group
CRON
|
-3.8 | $ 2.58 | 1.18 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-34.9 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-8.75 | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
-2.16 | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
-1.29 | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
-26.69 | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-65.18 | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-31.31 | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
-166.41 | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-23.59 | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-47.81 | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-22.86 | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
-41.71 | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
0.17 | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
-6.41 | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
0.25 | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-16.12 | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
21.06 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-38.66 | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-61.05 | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
-8.65 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-32.94 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-14.58 | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
-60.18 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-74.97 | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-25.25 | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Tilray
TLRY
|
-33.73 | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
-62.57 | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
4.16 | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
-1.44 | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
-64.44 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-63.1 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-9.3 | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
-104.78 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-10.28 | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-1.51 | $ 2.07 | 0.98 % | $ 23.9 M | USA |